Eva Yin

On September 25, 2026, the U.S. Food and Drug Administration (FDA) released draft guidance that sets out the agency’s recommendations on nonclinical testing, clinical data, and labeling for premarket submissions involving certain robotically assisted surgical devices (RASDs). The FDA is accepting comments through November 24, 2026. Like all draft guidance, the document is not binding on the FDA or the public.